Skip to main content

Table 1 Clinical, radiological, and CSF data at first episode of LETM

From: Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies

Demographic dataWhole cohortNon-relapsing patients in the first 18 monthsRelapsing patients in the first 18 months
n534112
Female, n (%)28 (52.8)22 (54%)6 (50%)
Age at onset, years median (range)38 (16.5–80)38 (16.5–80)43.2 (26–65)
Follow-up, years median (range)3.94 (1.5–12)2.88 (1.5–11.3)5.98 (3.91–12)
EDSS at nadir, median (range)6 (1–8.5)6.5 (1–8.5)5.25 (1–8.5)
Spinal cord MRI dataa
·  Cervical only761
·  Thoracic only18144
·  Lumbar only330
·  Cervical and thoracic14104
·  Cervical, thoracic and lumbar761
·  Thoracic and lumbar422
·  Cervical involvement, n (%)28 (53%)22 (54%)6 (50%)
·  Thoracic involvement, n (%)43 (81%)32 (78%)11 (92%)
·  Lumbar involvement, n (%)14 (26%)11 (27%)3 (25%)
Laboratory datab
 CSF OCB, n = 50, n (%)15 (30%)12/38 (32%)3/12 (25%)
 CSF pleocytosis (> 5 cells/mm3), n = 52, n (%)28 (54%)22/40 (55%)6/12 (50%)
 Proteinorachy (> 0.5 g/L), n = 51, n (%)24 (47%)18/39 (46%)6/12 (50%)
  1. LETM longitudinal extensive transverse myelitis, y years, m months, EDSS Expanded Disability Status Scale, CSF cerebrospinal fluid, OCB oligoclonal bands
  2. aSpinal cord MRI performed in the first month after symptoms onset
  3. bLumbar puncture performed during the first episode of LETM